XML 25 R12.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

12 Months Ended

Dec. 31, 2024

5.Balance Sheet Components

Property and Equipment, Net

Property and equipment, net consisted of the following:


	December 31,
(in thousands)	2024		2023
Machinery and equipment	$	13,437	$	13,124
Computer equipment and software		3,582		3,546
Furniture and fixtures		1,055		1,055
Leasehold improvements		5,751		5,751
Finance lease right of use assets		—		2,294
Total property and equipment		23,825		25,770
Accumulated depreciation and amortization		(20,988)		(20,651)
Property and equipment, net	$	2,837	$	5,119

Depreciation and amortization expense related to property and equipment, net was $1.8 million, $3.2 million and $3.6 million in 2024, 2023 and 2022, respectively. There were no material impairments of property and equipment in 2024, 2023 and 2022.

As of December 31, 2024 and 2023, the net book value of software implementation costs related to hosting arrangements was $2.0 million and $3.2 million, respectively, and the amortization expense was immaterial for all periods presented.

Intangible Assets, Net

Intangible assets, net consisted of the following:


	December 31,
(in thousands)	2024		2023
Finite-lived assets, net of accumulated amortization of $2,719 and $639, as of December 31, 2024 and 2023, respectively	$	24,787	$	41,871
Indefinite-lived assets - in-process research and development		28,859		28,859
Goodwill		—		943
Total Intangible assets, net	$	53,646	$	71,673

Amortization expense related to finite-lived intangible assets was $3.4 million during the year ended December 31, 2024 and immaterial for the years ended December 31, 2023 and 2022. As of December 31, 2024, amortization expense related to finite-lived assets for each of the five succeeding fiscal years is expected to be approximately $2.7 million. The weighted average remaining life of the finite-lived assets is 9.4 years on December 31, 2024.

In connection with the CIMERLI Sale on March 1, 2024, a finite-lived asset, net of $2.1 million and goodwill of $0.9 million were derecognized. In connection with the YUSIMRY Sale on June 26, 2024, a finite-lived asset with a net value of $0.9 million was derecognized.

The exclusive license of NZV930 to Novartis Institutes, acquired as part of the Surface Acquisition, was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, the Company recognized an impairment charge of $10.6 million for the carrying value of the Novartis Institutes out-license during the three months ended March 31, 2024, which was classified within selling, general and administrative expense in the consolidated statements of operations.

No impairment charges were recognized for goodwill or intangible assets during 2023 or 2022.

Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following:


	December 31,
(in thousands)	2024		2023
Accrued commercial and research and development manufacturing	$	12,449	$	23,470
Accrued co-development costs and milestone payments		12,500		26,812
Accrued royalties		1,498		42,031
Royalty fee derivative liability (Notes 3 and 8)		13,620		—
Revenue participation liability, current (Note 8)		1,148		—
Accrued other		17,382		7,628
Lease liabilities, current		1,691		2,145
Contingent consideration, current		—		3,300
Total Accrued and other current liabilities	$	60,288	$	105,386

Other Liabilities, Non-current

Other liabilities, non-current consisted of the following:


	December 31,
(in thousands)	2024		2023
Contingent consideration, non-current	$	632	$	1,172
Deferred tax liability (Note 13)		1,102		1,102
Revenue participation liability, non-current (Note 8)		27,595		—
Other		—		10,287
Total Other liabilities, non-current	$	29,329	$	12,561